Session of 2020

SENATE BILL No. 449

By Committee on Agriculture and Natural Resources

2-14

1 AN ACT concerning controlled substances; relating to cannabis; removing 2 certain products that contain a delta-9 tetrahydrocannabinol 3 concentration of up to 0.3% on a dry weight basis from the list of 4 controlled substances listed in schedule I of the uniform controlled 5 substances act; amending K.S.A. 2019 Supp. 21-5701, 65-4101 and 65-6 4105 and repealing the existing sections. 7 8 Be it enacted by the Legislature of the State of Kansas: 9 Section 1. K.S.A. 2019 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2019 Supp. 21-5701 through 21-10 11 5717, and amendments thereto: (a) "Controlled substance" means any 12 drug, substance or immediate precursor included in any of the schedules 13 designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, 14 and amendments thereto. 15 "Controlled substance analog" means a substance that is (b) (1) intended for human consumption, and at least one of the following: 16 (A) The chemical structure of the substance is substantially similar to 17 18 the chemical structure of a controlled substance listed in or added to the 19 schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 20 thereto: 21 (B) the substance has a stimulant, depressant or hallucinogenic effect 22 on the central nervous system substantially similar to the stimulant, 23 depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-24 25 4105 or 65-4107, and amendments thereto; or 26 (C) with respect to a particular individual, such individual represents 27 or intends the substance to have a stimulant, depressant or hallucinogenic 28 effect on the central nervous system substantially similar to the stimulant, 29 depressant or hallucinogenic effect on the central nervous system of a 30 controlled substance included in the schedules designated in K.S.A. 65-31 4105 or 65-4107, and amendments thereto. 32 (2) "Controlled substance analog" does not include: 33 (A) A controlled substance; 34 (B) a substance for which there is an approved new drug application; 35 or 36 (C) a substance with respect to which an exemption is in effect for

investigational use by a particular person under section 505 of the federal
 food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with
 respect to the substance is permitted by the exemption.

4 (c) "Cultivate" means the planting or promotion of growth of five or 5 more plants that contain or can produce controlled substances.

6 (d) "Distribute" means the actual, constructive or attempted transfer 7 from one person to another of some item whether or not there is an agency 8 relationship. "Distribute" includes, but is not limited to, sale, offer for sale 9 or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or 10 prescribing a controlled substance as authorized by the pharmacy act of the 11 12 state of Kansas, the uniform controlled substances act or otherwise 13 authorized by law.

14

(e) "Drug" means:

(1) Substances recognized as drugs in the official United States
 pharmacopeia, official homeopathic pharmacopoeia of the United States or
 official national formulary or any supplement to any of them;

18 (2) substances intended for use in the diagnosis, cure, mitigation,19 treatment or prevention of disease in humans or animals;

(3) substances, other than food, intended to affect the structure or anyfunction of the body of humans or animals; and

(4) substances intended for use as a component of any article
specified in paragraph (1), (2) or (3). It does not include devices or their
components, parts or accessories.

25 (f) "Drug paraphernalia" means all equipment and materials of any kind that are used, or primarily intended or designed for use in planting, 26 27 propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, 28 analyzing, packaging, repackaging, storing, containing, concealing, 29 injecting, ingesting, inhaling or otherwise introducing into the human body 30 31 a controlled substance and in violation of this act. "Drug paraphernalia" 32 shall include, but is not limited to:

(1) Kits used or intended for use in planting, propagating, cultivating,
 growing or harvesting any species of plant that is a controlled substance or
 from which a controlled substance can be derived;

(2) kits used or intended for use in manufacturing, compounding,
 converting, producing, processing or preparing controlled substances;

(3) isomerization devices used or intended for use in increasing thepotency of any species of plant that is a controlled substance;

40 (4) testing equipment used or intended for use in identifying or in 41 analyzing the strength, effectiveness or purity of controlled substances;

42 (5) scales and balances used or intended for use in weighing or 43 measuring controlled substances; 1 (6) diluents and adulterants, including, but not limited to, quinine 2 hydrochloride, mannitol, mannite, dextrose and lactose that are used or 3 intended for use in cutting controlled substances;

- 4 (7) separation gins and sifters used or intended for use in removing 5 twigs and seeds from or otherwise cleaning or refining marijuana;
- 6 (8) blenders, bowls, containers, spoons and mixing devices used or 7 intended for use in compounding controlled substances;
- 8 (9) capsules, balloons, envelopes, bags and other containers used or 9 intended for use in packaging small quantities of controlled substances;
- 10 (10) containers and other objects used or intended for use in storing 11 or concealing controlled substances;
- (11) hypodermic syringes, needles and other objects used or intended
 for use in parenterally injecting controlled substances into the human
 body;
- (12) objects used or primarily intended or designed for use in
 ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish,
 hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into
 the human body, such as:
- (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with
 or without screens, permanent screens, hashish heads or punctured metal
 bowls;
- (B) water pipes, bongs or smoking pipes designed to draw smokethrough water or another cooling device;
- (C) carburetion pipes, glass or other heat resistant tubes or any other
 device used, intended to be used or designed to be used to cause
 vaporization of a controlled substance for inhalation;
- 27

31

- (D) smoking and carburetion masks;
- 28 (E) roach clips, objects used to hold burning material, such as a 29 marijuana cigarette, that has become too small or too short to be held in 30 the hand;
 - (F) miniature cocaine spoons and cocaine vials;
- 32 (G) chamber smoking pipes;
- 33 (H) carburetor smoking pipes;
- 34 (I) electric smoking pipes;
- 35 (J) air-driven smoking pipes;
- 36 (K) chillums;
- 37 (L) bongs;
- 38 (M) ice pipes or chillers;
- 39 (N) any smoking pipe manufactured to disguise its intended purpose;
- 40 (O) wired cigarette papers; or
- 41 (P) cocaine freebase kits.
- 42 "Drug paraphernalia" shall not include any products, chemicals or
- 43 materials described in K.S.A. 2019 Supp. 21-5709(a), and amendments

1 thereto.

2 (g) "Immediate precursor" means a substance that the state board of 3 pharmacy has found to be and by rules and regulations designates as being 4 the principal compound commonly used or produced primarily for use and 5 that is an immediate chemical intermediary used or likely to be used in the 6 manufacture of a controlled substance, the control of which is necessary to 7 prevent, curtail or limit manufacture.

8

(h) "Isomer" means all enantiomers and diastereomers.

9 (i) "Manufacture" means the production, preparation, propagation, 10 compounding, conversion or processing of a controlled substance either 11 directly or indirectly or by extraction from substances of natural origin or 12 independently by means of chemical synthesis or by a combination of 13 extraction and chemical synthesis. "Manufacture" does not include:

(1) The preparation or compounding of a controlled substance by an
individual for the individual's own lawful use or the preparation,
compounding, packaging or labeling of a controlled substance:

(A) By a practitioner or the practitioner's agent pursuant to a lawful
order of a practitioner as an incident to the practitioner's administering or
dispensing of a controlled substance in the course of the practitioner's
professional practice; or

(B) by a practitioner or by the practitioner's authorized agent under
such practitioner's supervision for the purpose of or as an incident to
research, teaching or chemical analysis or by a pharmacist or medical care
facility as an incident to dispensing of a controlled substance; or

(2) the addition of diluents or adulterants, including, but not limited
to, quinine hydrochloride, mannitol, mannite, dextrose or lactose that are
intended for use in cutting a controlled substance.

28 "Marijuana" means any of the following that contains a delta-9 (i) 29 tetrahydrocannabinol concentration that exceeds 0.3% on a dry weight 30 basis: All parts of all varieties of the plant Cannabis whether growing or 31 not, the seeds thereof, the resin extracted from any part of the plant and 32 every compound, manufacture, salt, derivative, mixture or preparation of 33 the plant, its or of the seeds or resin of the plant. "Marijuana" does not 34 include: (1) The mature stalks of the plant, fiber produced from the stalks, 35 oil or cake made from the seeds of the plant, any other compound, 36 manufacture, salt, derivative, mixture or preparation of the mature stalks, 37 except the resin extracted therefrom, fiber, oil or cake or the sterilized seed 38 of the plant that is incapable of germination; (2) any substance listed in-39 schedules II through V of the uniform controlled substances act; (3)eannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-40 41 eyelohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as defined in K.S.A. 2019 Supp. 2-3901, and amendments thereto, when-42

43 cultivated, produced, possessed or used for activities authorized by the

1 commercial industrial hemp act any of the following that contains a delta-

9 tetrahydrocannabinol concentration of not more than 0.3% on a dry
weight basis: All parts of all varieties of the plant Cannabis whether
growing or not, the seeds thereof, the resin extracted from any part of the
plant and every compound, manufacture, salt, derivative, mixture or
preparation of the plant or of the seeds or resin of the plant.

7

(k) "Minor" means a person under 18 years of age.

8 (1) "Narcotic drug" means any of the following whether produced 9 directly or indirectly by extraction from substances of vegetable origin or 10 independently by means of chemical synthesis or by a combination of 11 extraction and chemical synthesis:

12 (1) Opium and opiate and any salt, compound, derivative or 13 preparation of opium or opiate;

(2) any salt, compound, isomer, derivative or preparation thereof that
is chemically equivalent or identical with any of the substances referred to
in paragraph (1) but not including the isoquinoline alkaloids of opium;

17

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative or preparation of
 coca leaves and any salt, compound, isomer, derivative or preparation
 thereof that is chemically equivalent or identical with any of these
 substances, but not including decocainized coca leaves or extractions of
 coca leaves that do not contain cocaine or ecgonine.

(m) "Opiate" means any substance having an addiction-forming or 23 24 addiction-sustaining liability similar to morphine or being capable of 25 conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as 26 controlled under K.S.A. 65-4102, and amendments thereto, the 27 28 dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory 29 30 forms

(n) "Opium poppy" means the plant of the species Papaversomniferum l. except its seeds.

33 (o) "Person" means an individual, corporation, government or
 34 governmental subdivision or agency, business trust, estate, trust,
 35 partnership, association or any other legal entity.

(p) "Poppy straw" means all parts, except the seeds, of the opiumpoppy, after mowing.

(q) "Possession" means having joint or exclusive control over an item
with knowledge of and intent to have such control or knowingly keeping
some item in a place where the person has some measure of access and
right of control.

42 (r) "School property" means property upon which is located a 43 structure used by a unified school district or an accredited nonpublic 1 school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This 2 3 definition shall not be construed as requiring that school be in session or 4 that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the 5 6 time of any alleged criminal act. If the structure or property meets the 7 above definition, the actual use of that structure or property at the time 8 alleged shall not be a defense to the crime charged or the sentence 9 imposed.

(s) "Simulated controlled substance" means any product that
 identifies itself by a common name or slang term associated with a
 controlled substance and that indicates on its label or accompanying
 promotional material that the product simulates the effect of a controlled
 substance.

Sec. 2. K.S.A. 2019 Supp. 65-4101 is hereby amended to read as follows: 65-4101. As used in this act: (a) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:

20 (1) A practitioner or pursuant to the lawful direction of a practitioner;21 or

(2) the patient or research subject at the direction and in the presenceof the practitioner.

(b) "Agent" means an authorized person who acts on behalf of or at
the direction of a manufacturer, distributor or dispenser. It does not include
a common carrier, public warehouseman or employee of the carrier or
warehouseman.

(c) "Application service provider" means an entity that sells
 electronic prescription or pharmacy prescription applications as a hosted
 service where the entity controls access to the application and maintains
 the software and records on its server.

32

(d) "Board" means the state board of pharmacy.

(e) "Bureau" means the bureau of narcotics and dangerous drugs,
United States department of justice, or its successor agency.

(f) "Controlled substance" means any drug, substance or immediate
precursor included in any of the schedules designated in K.S.A. 65-4105,
65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

(g) (1) "Controlled substance analog" means a substance that isintended for human consumption, and at least one of the following:

40 (A) The chemical structure of the substance is substantially similar to 41 the chemical structure of a controlled substance listed in or added to the 42 schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 43 thereto; 1 (B) the substance has a stimulant, depressant or hallucinogenic effect 2 on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a 3 4 controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or 5

6 (C) with respect to a particular individual, such individual represents 7 or intends the substance to have a stimulant, depressant or hallucinogenic 8 effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a 9 controlled substance included in the schedules designated in K.S.A. 65-10 4105 or 65-4107, and amendments thereto. 11 (2) "Controlled substance analog" does not include:

12 13

(A) A controlled substance;

14 (B) a substance for which there is an approved new drug application; 15 or

16 (C) a substance with respect to which an exemption is in effect for 17 investigational use by a particular person under section 505 of the federal 18 food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with 19 respect to the substance is permitted by the exemption.

(h) "Counterfeit substance" means a controlled substance that, or the 20 21 container or labeling of which, without authorization bears the trademark, 22 trade name or other identifying mark, imprint, number or device or any 23 likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance. 24

25 "Cultivate" means the planting or promotion of growth of five or (i) more plants that contain or can produce controlled substances. 26

27 (i) "DEA" means the U.S. department of justice, drug enforcement 28 administration.

(k) "Deliver" or "delivery" means the actual, constructive or 29 30 attempted transfer from one person to another of a controlled substance, 31 whether or not there is an agency relationship.

32 (1) "Dispense" means to deliver a controlled substance to an ultimate 33 user or research subject by or pursuant to the lawful order of a practitioner, 34 including the packaging, labeling or compounding necessary to prepare the 35 substance for that delivery, or pursuant to the prescription of a mid-level 36 practitioner.

37 "Dispenser" means a practitioner or pharmacist who dispenses, or (m)38 a physician assistant who has authority to dispense prescription-only drugs 39 in accordance with K.S.A. 65-28a08(b), and amendments thereto.

40 "Distribute" means to deliver other than by administering or (n) 41 dispensing a controlled substance.

42

(o) "Distributor" means a person who distributes.

43 (p) "Drug" means: (1) Substances recognized as drugs in the official 1 United States pharmacopeia, official homeopathic pharmacopoeia of the 2 United States or official national formulary or any supplement to any of 3 them; (2) substances intended for use in the diagnosis, cure, mitigation, 4 treatment or prevention of disease in human or animals; (3) substances 5 (other than food) intended to affect the structure or any function of the 6 body of human or animals; and (4) substances intended for use as a 7 component of any article specified in paragraph (1), (2) or (3). It does not 8 include devices or their components, parts or accessories.

9 (q) "Immediate precursor" means a substance that the board has 10 found to be and by rule and regulation designates as being the principal compound commonly used or produced primarily for use and that is an 11 12 immediate chemical intermediary used or likely to be used in the 13 manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture. 14

"Electronic prescription" means an electronically prepared 15 (r) 16 prescription that is authorized and transmitted from the prescriber to the 17 pharmacy by means of electronic transmission.

18 (s) "Electronic prescription application" means software that is used 19 to create electronic prescriptions and that is intended to be installed on the 20 prescriber's computers and servers where access and records are controlled 21 by the prescriber.

22 "Electronic signature" means a confidential personalized digital (t) 23 key, code, number or other method for secure electronic data transmissions 24 that identifies a particular person as the source of the message, 25 authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission. 26

27 (u) "Electronic transmission" means the transmission of an electronic 28 prescription, formatted as an electronic data file, from a prescriber's 29 electronic prescription application to a pharmacy's computer, where the 30 data file is imported into the pharmacy prescription application.

31 (v) "Electronically prepared prescription" means a prescription that is 32 generated using an electronic prescription application.

33 (w) "Facsimile transmission" or "fax transmission" means the 34 transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but 35 36 is not limited to, transmission of a written prescription between the 37 prescriber's fax machine and the pharmacy's fax machine; transmission of 38 an electronically prepared prescription from the prescriber's electronic 39 prescription application to the pharmacy's fax machine, computer or 40 printer; or transmission of an electronically prepared prescription from the 41 prescriber's fax machine to the pharmacy's fax machine, computer or 42 printer. 43

(x) "Intermediary" means any technology system that receives and

9

1 transmits an electronic prescription between the prescriber and the 2 pharmacy.

3

(y) "Isomer" means all enantiomers and diastereomers.

4 (z)"Manufacture" means the production, propagation, 5 compounding, conversion or processing of a controlled substance either 6 directly or indirectly or by extraction from substances of natural origin or 7 independently by means of chemical synthesis or by a combination of 8 extraction and chemical synthesis and includes any packaging or 9 repackaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a 10 controlled substance by an individual for the individual's own lawful use 11 12 or the preparation, compounding, packaging or labeling of a controlled 13 substance:

(1) By a practitioner or the practitioner's agent pursuant to a lawful
 order of a practitioner as an incident to the practitioner's administering or
 dispensing of a controlled substance in the course of the practitioner's
 professional practice; or

(2) by a practitioner or by the practitioner's authorized agent under
such practitioner's supervision for the purpose of or as an incident to
research, teaching or chemical analysis or by a pharmacist or medical care
facility as an incident to dispensing of a controlled substance.

22 (aa) "Marijuana" means any of the following that contains a delta-9 23 tetrahydrocannabinol concentration that exceeds 0.3% on a dry weight 24 basis: All parts of all varieties of the plant Cannabis whether growing or 25 not, the seeds thereof, the resin extracted from any part of the plant and 26 every compound, manufacture, salt, derivative, mixture or preparation of 27 the plant, its or of the seeds or resin of the plant. It "Marijuana" does not 28 include: (1) The mature stalks of the plant, fiber produced from the stalks, 29 oil or cake made from the seeds of the plant, any other compound, 30 manufacture, salt, derivative, mixture or preparation of the mature stalks, 31 except the resin extracted therefrom, fiber, oil or cake or the sterilized seed 32 of the plant that is incapable of germination; (2) any substance listed in-33 schedules II through V of the uniform controlled substances act; (3)eannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-34 35 evelohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as 36 defined in K.S.A. 2019 Supp. 2-3901, and amendments thereto, when-37 eultivated, produced, possessed or used for activities authorized by the 38 commercial industrial hemp act any of the following that contains a delta-39 9 tetrahydrocannabinol concentration of not more than 0.3% on a dry 40 weight basis: All parts of all varieties of the plant Cannabis whether 41 growing or not, the seeds thereof, the resin extracted from any part of the 42 plant and every compound, manufacture, salt, derivative, mixture or 43 preparation of the plant or of the seeds or resin of the plant.

1 (bb) "Medical care facility" shall have the meaning ascribed to that 2 term in K.S.A. 65-425, and amendments thereto.

(cc) "Mid-level practitioner" means a certified nurse-midwife 3 engaging in the independent practice of midwifery under the independent 4 5 practice of midwifery act, an advanced practice registered nurse issued a 6 license pursuant to K.S.A. 65-1131, and amendments thereto, who has 7 authority to prescribe drugs pursuant to a written protocol with a 8 responsible physician under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the physician assistant licensure act who 9 has authority to prescribe drugs pursuant to a written agreement with a 10 supervising physician under K.S.A. 65-28a08, and amendments thereto. 11

(dd) "Narcotic drug" means any of the following whether produced
 directly or indirectly by extraction from substances of vegetable origin or
 independently by means of chemical synthesis or by a combination of
 extraction and chemical synthesis:

16 (1) Opium and opiate and any salt, compound, derivative or 17 preparation of opium or opiate;

(2) any salt, compound, isomer, derivative or preparation thereof that
 is chemically equivalent or identical with any of the substances referred to
 in paragraph (1) but not including the isoquinoline alkaloids of opium;

21

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.

(ee) "Opiate" means any substance having an addiction-forming or
addiction-sustaining liability similar to morphine or being capable of
conversion into a drug having addiction-forming or addiction-sustaining
liability. It does not include, unless specifically designated as controlled
under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer
of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does
include its racemic and levorotatory forms.

34 (ff) "Opium poppy" means the plant of the species Papaver35 somniferum l. except its seeds.

(gg) "Person" means an individual, corporation, government, or
governmental subdivision or agency, business trust, estate, trust,
partnership or association or any other legal entity.

(hh) "Pharmacist" means any natural person licensed under K.S.A.
65-1625 et seq., and amendments thereto, to practice pharmacy.

41 (ii) "Pharmacist intern" means: (1) A student currently enrolled in an
42 accredited pharmacy program; (2) a graduate of an accredited pharmacy
43 program serving such person's internship; or (3) a graduate of a pharmacy

program located outside of the United States that is not accredited and who
 had successfully passed equivalency examinations approved by the board.

3 (jj) "Pharmacy prescription application" means software that is used 4 to process prescription information, is installed on a pharmacy's computers 5 and servers, and is controlled by the pharmacy.

6 (kk) "Poppy straw" means all parts, except the seeds, of the opium 7 poppy, after mowing.

8 (ll) "Practitioner" means a person licensed to practice medicine and 9 surgery, dentist, podiatrist, veterinarian, optometrist, or scientific 10 investigator or other person authorized by law to use a controlled 11 substance in teaching or chemical analysis or to conduct research with 12 respect to a controlled substance.

13

(mm) "Prescriber" means a practitioner or a mid-level practitioner.

(nn) "Production" includes the manufacture, planting, cultivation,growing or harvesting of a controlled substance.

16 (oo) "Readily retrievable" means that records kept by automatic data 17 processing applications or other electronic or mechanized recordkeeping 18 systems can be separated out from all other records within a reasonable 19 time not to exceed 48 hours of a request from the board or other authorized 20 agent or that hard-copy records are kept on which certain items are 21 asterisked, redlined or in some other manner visually identifiable apart 22 from other items appearing on the records.

(pp) "Ultimate user" means a person who lawfully possesses a
 controlled substance for such person's own use or for the use of a member
 of such person's household or for administering to an animal owned by
 such person or by a member of such person's household.

27 Sec. 3. K.S.A. 2019 Supp. 65-4105 is hereby amended to read as 28 follows: 65-4105. (a) The controlled substances listed in this section are 29 included in schedule I and the number set forth opposite each drug or 30 substance is the DEA controlled substances code that has been assigned to 31 it.

(b) Any of the following opiates, including their isomers, esters,
ethers, salts, and salts of isomers, esters and ethers, unless specifically
excepted, whenever the existence of these isomers, esters, ethers and salts
is possible within the specific chemical designation:

36	(1)	Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
37		phenylacetamide)
38	(2)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
39		piperidinyl]-N-phenylacetamide)
40	(3)	Acetylmethadol
41	(4)	Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide;
42		acryloylfentanyl)
43	(5)	AH-7921 (3,4-dichloro-N-[(1-

1		1	1
1	(0)	dimethylamino)cyclohexylmethyl]benzamide)	
2	(6)	Allylprodine	
3 4	(7)	Alphacetylmethadol	3
4 5			
5 6	(8)	acetylmethadol, levomethadyl acetate or LAAM) Alphameprodine	1
7	(8)	Alphamethadol	
8	(9) (10)	1	5
9	(10)	piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-	
10		propanilido) piperidine)	1
11	(11)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-	4
12	(11)	piperidinyl]-N-phenylpropanamide)	2
12	(12)	Benzethidine	
14		Betacetylmethadol	
15		Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]	
16	(11)	N-phenylpropanamide)	
17	(15)	Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-	
18	(-)	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)983	1
19	(16)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-	
20	()	yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)	6
21	(17)	Betameprodine	
22		Betamethadol	
23	(19)	Betaprodine	1
24	(20)	Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
25		phenylbutyramide)	
26		Clonitazene	2
27	(22)	Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
28		phenylcyclopentanecarboxamide)	
29	(23)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
30		phenylcyclopropanecarboxamide)	
31	~ /	Dextromoramide	
32		Diampromide	
33	~ /	Diethylthiambutene	
34		Difenoxin	
35		Dimenoxadol	
36	· · ·	Dimepheptanol	
37		Dimethylthiambutene	
38		Dioxaphetyl butyrate	
39		Dipipanone	
40		Ethylmethylthiambutene	
41		Etonitazene	
42		Etoxeridine	3
43	(36)	Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-	

1		carboxamide)
2	(37)	Furethidine
3		Hydroxypethidine
4		Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
5		phenylisobutyramide)
6	(40)	Ketobemidone
7	(41)	Levomoramide
8	(42)	Levophenacylmorphan
9	(43)	Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-
10		N-phenylacetamide)
11	(44)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-
12		phenylpropanamide)
13	(45)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-
14		piperidinyl]-N-phenylpropanamide)
15		Morpheridine
16	(47)	Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-
17		4-yl)acetamide)
18	(48)	O-desmethyltramadol
19		Some trade or other names: 2-((dimethylamino)methyl-1-(3-
20		hydroxyphenyl)cyclohexanol;3-(2-((dimethylamino)methyl)-1-
21		hydroxycyclohexyl)phenol
22	(49)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)9661
23		MT-45 (1-cychohexyl-4-(1,2-diphenylethyl)piperazine)
24		Noracymethadol
25		Norlevorphanol
26		Normethadone
27		Norpipanone
28	(55)	Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-
29		4-yl)propionamide; 2-fluorofentanyl)
30	(56)	Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-
31	<i></i>	phenethylpiperidin-4-yl)isobutyramide)
32	(57)	Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
33		phenethylpiperidin-4-yl)butyramide)
34	(58)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
35	(= 0)	piperidinyl]propanamide)
36	(59)	Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
37		phenethylpiperidin-4-yl)isobutyramide,
38	((0))	4-fluoroisobutyryl fentanyl)
39	(60)	Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-
40	((1)	phenethylpiperidin-4-yl)butyramide)
41		PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine)
42	· · ·	Phenadoxone
43	(63)	Phenampromide

1	$(\boldsymbol{\epsilon}\boldsymbol{\Lambda})$	Phenomorphan
1	· · ·	1
2		Phenoperidine
3	· · ·	Piritramide
4		Proheptazine
5		Properidine
6		Propiram
7	· /	Racemoramide
8	(71)	Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
9		phenyltetrahydrofuran-2-carboxamide)
10	(72)	
11		propanamide)
12	(73)	Tilidine
13	(74)	Trimeperidine
14	(75)	U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
15		methylbenzamide)9547
16	(76)	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
17		phenylpentanamide)
18		e) Any of the following opium derivatives, their salts, isomers and
19	salts	of isomers, unless specifically excepted, whenever the existence of
20	these	e salts, isomers and salts of isomers is possible within the specific
21	chem	nical designation:
22	(1)	Acetorphine
23	(2)	Acetyldihydrocodeine
24	(3)	Benzylmorphine
25	(4)	Codeine methylbromide
26	(5)	Codeine-N-Oxide
27	(6)	Cyprenorphine
28	(7)	Desomorphine
29	(8)	Dihydromorphine
30	(9)	Drotebanol
31	(10)	Etorphine (except hydrochloride salt)
32	(11)	Heroin
33	(12)	Hydromorphinol
34	(13)	Methyldesorphine
35	(14)	Methyldihydromorphine
36	(15)	Morphine methylbromide
37	(16)	Morphine methylsulfonate
38		Morphine-N-Oxide
39		Myrophine
40	(10)	Nicocodeine
41		Nicomorphine
42		Normorphine
43		Pholcodine
.5	(22)	1 Holoowino

1	(23)	Thebacon
2	· · · · ·	d) Any material, compound, mixture or preparation that contains any
3	quan	tity of the following hallucinogenic substances, their salts, isomers
4		salts of isomers, unless specifically excepted, whenever the existence
5		lese salts, isomers and salts of isomers is possible within the specific
6		nical designation:
7	(1)	Alpha-ethyltryptamine 7249 Some trade or other names:
8	()	etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-
9		aminobutyl) indole; α-ET; and AET.
10	(2)	4-bromo-2,5-dimethoxy-amphetamine
11	()	Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-
12		methylphenethylamine; 4-bromo-2,5-DMA.
13	(3)	2,5-dimethoxyamphetamine
14	(-)	Some trade or other names: 2,5-dimethoxy-alpha-methyl-
15		phenethylamine; 2,5-DMA.
16	(4)	4-methoxyamphetamine
17	()	Some trade or other names: 4-methoxy-alpha-methylphene-
18		thylamine; paramethoxyamphetamine; PMA.
19	(5)	5-methoxy-3,4-methylenedioxy-amphetamine
20	(6)	4-methyl-2,5-dimethoxy-amphetamine
21	(-)	Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-
22		methylphenethylamine; "DOM"; and "STP".
23	(7)	3,4-methylenedioxy amphetamine
24	(8)	3,4-methylenedioxymethamphetamine (MDMA)
25	(9)	3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-
26	()	alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA,
27		MDE, and MDEA)
28	(10)	
29		hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine, and
30		N-hydroxy MDA)
31	(11)	3,4,5-trimethoxy amphetamine
32	(12)	Bufotenine
33		Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-
34		hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-
35		dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.
36	(13)	Diethyltryptamine
37		Some trade or other names: N,N-Diethyltryptamine; DET.
38	(14)	Dimethyltryptamine
39		Some trade or other names: DMT.
40	(15)	Ibogaine
41		Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-
42		octahydro-2-methoxy-6,9-methano-5H-pyrido[1',2':1,2]azepino[5,4-
43		b]indole; Tabernanthe iboga

1	(16)	Lysergic acid diethylamide
2		Marijuana
3		Mescaline
4		Parahexyl
5	(19)	Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-tetrahydro-
6		6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.
7	(20)	Peyote
8	(20)	Meaning all parts of the plant presently classified botanically as
9		Lophophora williamsii Lemaire, whether growing or not, the seeds
10		thereof, any extract from any part of such plant, and every
11		compound, manufacture, salts, derivative, mixture or preparation of
12		such plant, its seeds or extracts.
13	(21)	N-ethyl-3-piperidyl benzilate
14		N-methyl-3-piperidyl benzilate
15		Psilocybin
16		Psilocyn
17	(21)	Some trade or other names: Psilocin.
18	(25)	Ethylamine analog of phencyclidine
19	(20)	Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine; (1-
20		phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
21		cyclohexamine; PCE.
22	(26)	Pyrrolidine analog of phencyclidine
23	()	Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine;
24		PCPy; PHP.
25	(27)	Thiophene analog of phencyclidine
26		Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
27		2-thienyl analog of phencyclidine; TPCP; TCP.
28	(28)	1-[1-(2-thienyl)-cyclohexyl] pyrrolidine
29	. ,	Some other names: TCPy.
30	(29)	2,5-dimethoxy-4-ethylamphetamine
31		Some trade or other names: DOET.
32	(30)	Salvia divinorum or salvinorum A; all parts of the plant presently
33		classified botanically as salvia divinorum, whether growing or not,
34		the seeds thereof, any extract from any part of such plant, and every
35		compound, manufacture, salts, derivative, mixture or preparation of
36		such plant, its seeds or extracts.
37	(31)	Datura stramonium, commonly known as gypsum weed or jimson
38		weed; all parts of the plant presently classified botanically as datura
39		stramonium, whether growing or not, the seeds thereof, any extract
40		from any part of such plant, and every compound, manufacture, salts,
41		derivative, mixture or preparation of such plant, its seeds or extracts.
42	(32)	N-benzylpiperazine7493
43		Some trade or other names: BZP.

SB 449

1	(33)	1-(3-[trifluoromethylphenyl])piperazine
2		Some trade or other names: TFMPP.
3		4-Bromo-2,5-dimethoxyphenethylamine
4	(35)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical
5		isomers, salts and salts of optical isomers
6		Alpha-methyltryptamine (other name: AMT)7432
7	(37)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers,
8		salts and salts of isomers
9		2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)7509
10		2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7508
11		2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)7519
12		2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)7518
13		2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)7385
14		2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 7532
15		2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)7517
16		2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)7521
17		2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)7524
18	(47)	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)7431
19		Some trade or other names: 5-methoxy-3-[2-(dimethylamino)
20		ethyl]indole.
21	(48)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
22		methoxybenzyl)ethanamine7538
23		Some trade or other names: 25I–NBOMe; 2C–I–NBOMe; 25I;
24		Cimbi–5.
25	(49)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
26		methoxybenzyl)ethanamine7537
27		Some trade or other names: 25C–NBOMe; 2C–C–NBOMe; 25C;
28		Cimbi–82.
29	(50)	
30		methoxybenzyl)ethanamine7536
31		Some trade or other names: 25B–NBOMe; 2C–B–NBOMe; 25B;
32		Cimbi–36.
33	(51)	2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
34		Some trade or other names: 25H-NBOMe.
35	(52)	2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
36		Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.
37	(53)	2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine
38		Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.
39	(e) Any material, compound, mixture or preparation that contains any
40		tity of the following substances having a depressant effect on the
41		al nervous system, including its salts, isomers, and salts of isomers
42		never the existence of such salts, isomers, and salts of isomers is
43	poss	ble within the specific chemical designation:

1	(1)	Etizolam
2		Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-
3	$\langle 0 \rangle$	6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
4	(2)	Mecloqualone
5 6	(3)	Methaqualone
0 7	(4)	f) Unless specifically excepted or unless listed in another schedule,
8		material, compound, mixture or preparation that contains any quantity
9	of t	he following substances having a stimulant effect on the central
10		ous system, including its salts, isomers and salts of isomers:
11	(1)	Aminorex
12		Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline or
13		4,5-dihydro-5-phenyl-2-oxazolamine
14	(2)	Fenethylline
15	(3)	N-ethylamphetamine
16	(4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-2-
17	(5)	oxazolamine)
18	(5)	N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-
19	(Ω)	benzeneethanamine; N,N-alpha-trimethylphenethylamine)1480
20	(6)	Cathinone (some other names: 2-amino-1-phenol-1-propanone,
21		alpha-amino propiophenone, 2-amino propiophenone and
22	(7)	norphedrone)
23 24	(7)	Any compound, except bupropion or compounds listed under a
24 25		different schedule, structurally derived from 2–aminopropan–1–one
26		by substitution at the 1-position with either phenyl, naphthyl, or
20 27		thiophene ring systems, whether or not the compound is further
28		modified in any of the following ways:
29		(A) By substitution in the ring system to any extent with alkyl,
30		alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
31		substituents, whether or not further substituted in the ring
32		system by one or more other univalent substituents;
33		(B) by substitution at the 3-position with an acyclic alkyl
34		substituent;
35		(C) by substitution at the 2-amino nitrogen atom with alkyl,
36		dialkyl, benzyl, or methoxybenzyl groups; or
37		(D) by inclusion of the 2-amino nitrogen atom in a cyclic
38		structure.
39	(g) Any material, compound, mixture or preparation that contains any
40	-	ntity of the following substances:
41	(1)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its
42		optical isomers, salts and salts of isomers
43	(2)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide

1		(thenylfentanyl), its optical isomers, salts and salts of isomers
2		n) Any of the following cannabinoids, their salts, isomers and salts
3		omers, unless specifically excepted, whenever the existence of these
4		, isomers and salts of isomers is possible within the specific chemical
5		gnation:
6	(1)	Tetrahydrocannabinols7370
7		Meaning tetrahydrocannabinols naturally contained in a plant of the
8		genus Cannabis (cannabis plant), as well as synthetic equivalents of
9		the substances contained in the plant, or in the resinous extractives of
10		Cannabis, sp. and/or synthetic substances, derivatives, and their
11		isomers with similar chemical structure and pharmacological activity
12		such as the following: Delta 1 cis or trans tetrahydrocannabinol, and
13		their optical isomers Delta 6 cis or trans tetrahydrocannabinol, and
14		their optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and
15		its optical isomers (Since nomenclature of these substances is not
16		internationally standardized, compounds of these structures,
17		regardless of numerical designation of atomic positions covered.),
18		except tetrahydrocannabinols in any of the following:
19		(A) Industrial hemp, as defined in K.S.A. 2019 Supp. 2-3901, and
20		amendments theretoAny of the following that contains a delta-
21		9 tetrahydrocannabinol concentration of not more than 0.3%
22		on a dry weight basis: All parts of all varieties of the plant
23		Cannabis whether growing or not, the seeds thereof, the resin
24		extracted from any part of the plant and every compound,
25		manufacture, salt, derivative, mixture or preparation of the
26		plant or of the seeds or resin of the plant; or
27		(B) solid waste, as defined in K.S.A. 65-3402, and amendments
28		thereto, and hazardous waste, as defined in K.S.A. 65-3430,
29		and amendments thereto, if such waste is the result of the
30		cultivation, production or processing of industrial hemp, as
31		defined in K.S.A. 2019 Supp. 2-3901, and amendments
32		thereto, and such waste contains a delta-9
33		tetrahydrocannabinol concentration of not more than 0.3%; or
34		(C) hemp products, as defined in K.S.A. 2019 Supp. 2-3901, and
35		amendments thereto, unless otherwise deemed unlawful-
36		pursuant to K.S.A. 2019 Supp. 2-3908, and amendments-
37		thereto.
38	(2)	Naphthoylindoles
39		Any compound containing a 3-(1-naphthoyl)indole structure with
40		substitution at the nitrogen atom of the indole ring by an alkyl,
41		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
42		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl
43		group, whether or not further substituted in the indole ring to any

1		extent and whether or not substituted in the benzyl or naphthyl ring
2		to any extent.
$\frac{2}{3}$	(3)	Naphthylmethylindoles
4	(\mathbf{J})	Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane
5		structure with substitution at the nitrogen atom of the indole ring by
6		an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
7		cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
8		morpholinyl)ethyl group whether or not further substituted in the
9		indole ring to any extent and whether or not substituted in the benzyl
10		or naphthyl ring to any extent.
11	(4)	Naphthoylpyrroles
12		Any compound containing a 3-(1-naphthoyl)pyrrole structure with
13		substitution at the nitrogen atom of the pyrrole ring by an alkyl,
14		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
16		group whether or not further substituted in the pyrrole ring to any
17		extent, whether or not substituted in the benzyl or naphthyl ring to
18		any extent.
19	(5)	Naphthylmethylindenes
20	()	Any compound containing a naphthylideneindene structure with
21		substitution at the 3-position of the indene ring by an alkyl,
22		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
23		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
24		group whether or not further substituted in the indene ring to any
25		extent, whether or not substituted in the benzyl or naphthyl ring to
26		any extent.
27	(6)	Phenylacetylindoles
28	(-)	Any compound containing a 3-phenylacetylindole structure with
29		substitution at the nitrogen atom of the indole ring by an alkyl,
30		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
31		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
32		group whether or not further substituted in the indole ring to any
33		extent, whether or not substituted in the benzyl or phenyl ring to any
34		extent, whether of not substituted in the benzyr of phenyr ring to any extent.
35	(7)	Cyclohexylphenols
36	()	Any compound containing a 2-(3-hydroxycyclohexyl)phenol
37		structure with substitution at the 5-position of the phenolic ring by an
38		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
39		cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
39 40		morpholinyl)ethyl group whether or not substituted in the cyclohexyl
40 41		ring to any extent.
41 42	(9)	Benzoylindoles
42 43	(8)	Any compound containing a 3-(benzoyl)indole structure with
43		Any compound containing a 5-(benzoyi)indole structure with

1 2 3 4		substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
5		extent and whether or not substituted in the benzyl or phenyl ring to
6		any extent.
7	(9)	2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-
8 9		1,4-benzoxazin-6-yl]-1-napthalenylmethanone. Some trade or other names: WIN 55,212-2.
9 10	(10)	9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-
10	(10)	6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
12		Some trade or other names: HU-210, HU-211.
13	(11)	Tetramethylcyclopropanoylindoles
14		Any compound containing a 3-tetramethylcyclopropanoylindole
15		structure with substitution at the nitrogen atom of the indole ring by
16		an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
17		cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
18		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-
19 20		3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or
20		not substituted in the benzyl or tetramethylcyclopropyl rings to any
22		extent.
23	(12)	Indole-3-carboxylate esters
24	()	Any compound containing a 1H-indole-3-carboxylate ester structure
25		with the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or
26		adamantyl group and substitution at the 1 position of the indole ring
27		by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
28		cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl or 2-(4-
29		morpholinyl)ethyl group, whether or not further substituted on the
30 31		indole ring to any extent and whether or not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantyl or benzyl groups to
32		any extent.
33	(13)	Indazole-3-carboxamides
34	(15)	Any compound containing a 1H-indazole-3-carboxamide structure
35		with substitution at the nitrogen of the carboxamide by a naphthyl,
36		quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-
37		yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1
38		position of the indazole ring by an alkyl, haloalkyl, cyanoalkyl,
39		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
40 41		piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indazole ring to any extent and whether or
41 42		not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantyl,
43		1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl
		$= \dots = 0$

1	groups to any extent.
2	(14) Indole-3-carboxamides
3	Any compound containing a 1H-indole-3-carboxamide structure with
4	substitution at the nitrogen of the carboxamide by a naphthyl,
5	quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-
6	yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1
7	position of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
8	alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
9	piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not
10	further substituted on the indole ring to any extent and whether or not
11	further substituted on the naphthyl, quinolinyl, isoquinolinyl,
12	adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or
13	benzyl groups to any extent.
14	(15) (1H-indazol-3-yl)methanones
15	Any compound containing a (1H-indazol-3-yl)methanone structure
16	with the carbonyl carbon bearing a naphthyl group and substitution at
17	the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl,
18	cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
19	piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not
20	further substituted on the indazole ring to any extent and whether or
21	not substituted on the naphthyl or benzyl groups to any extent.
22	Sec. 4. K.S.A. 2019 Supp. 21-5701, 65-4101 and 65-4105 are hereby
23	repealed.
24	Sec. 5. This act shall take effect and be in force from and after its
25	multipation in the Venera register

25 publication in the Kansas register.